Drug intelligence / Profile preview

miR-150-5p inhibitor

Development stage
Preclinical
Lead developer
Brown University
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

miR-150-5p inhibitor is a synthetic oligonucleotide-based agent designed to complementarily bind and neutralize the microRNA **miR-150-5p**. In the context of neuro-oncology research, miR-150-5p has been identified as a potential biomarker for brain tumors, including glioblastoma, meningioma, and brain metastases. Research indicates that miR-150-5p is significantly under-expressed in the serum of glioblastoma patients compared to healthy controls. Experimental inhibition of miR-150-5p in glioblastoma stem cells (GSCs) via lipid transfection has been shown to augment cell growth, viability, and self-renewal, suggesting that miR-150-5p may normally function as a tumor suppressor in this specific cellular context. These inhibitors are primarily utilized as research tools to investigate the functional role of miR-150-5p in oncogenesis and to validate its potential as a therapeutic target or diagnostic biomarker.

Other names
anti-miR-150-5panti-miR150-5panti-miR 150-5pantagomir-150-5pantagomir150-5pantagomir 150-5pmiR-150-5p antagomirmiR150-5p antagomirmiR 150-5p antagomir
02

Targets

miR-150-5p (MicroRNA 150-5p)

Beyond the preview

Go deeper on miR-150-5p inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-150-5p inhibitor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call